Our PheWAS results did not identify any other protective effects that would coincide with SGLT2 inhibition, such as heart failure, CKD, cardiovascular disease, weight management, and BP control.23, , , –27 Conversely, we did pick up a statistically significant association with infection/inflammation of internal prosthetic device, implant, and graft. The gene discussed is SLC5A2; the disease is chronic kidney disease.